Dejan Juric
MD
Co-Director, Termeer Center for Targeted Therapies
👥Biography 个人简介
Dejan Juric is a medical oncologist specializing in early-phase clinical trials in breast cancer, including first-in-human and expansion studies with patritumab deruxtecan (HER3-DXd, U3-1402), a next-generation ADC targeting HER3-low expression. His research has established HER3 as a broadly expressed and therapeutically actionable target in breast cancer regardless of HER2 status, complementing the HER2-low paradigm. He also leads research on PI3K pathway inhibitors and resistance mechanisms.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Dejan Juric 的研究动态
Follow Dejan Juric's research updates
留下邮箱，当我们发布与 Dejan Juric（Massachusetts General Hospital / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment